Carbidopa (also known as MK485, MK-485; trade name: Lodosyn; abbreviated as CD), a potent and competitive inhibitor of aromatic l-amino acid decarboxylase that does not cross the blood-brain barrier, is routinely administered with levodopa (LD) to patients with Parkinson disease (PD) to reduce the peripheral decarboxylation of LD to dopamine.

CAY 10465, an analog of resveratrol, is a novel, potent, selective and high-affinity AhR (aryl hydrocarbon receptor) agonist, with a Ki of 0.2 nM, and shows no effect on estrogen receptor (Ki >100000 nM).

Benvitimod (Tapinarof; WB1001; GSK2894512) is a naturally occurring aryl hydrocarbon receptor (AhR) agonist (EC50 = 13 nM) approved in China for treating plaque psoriasis.

PDM-2 (PDM2), a trans-resveratrol analog, is a novel selective, high-affinity aryl hydrocarbon receptor (AhR) antagonist with an Ki of 1.2±0.4 nM.

YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.